Tocagen — Forte Biosciences — Investor Presentation (December 2024)
49 slides from Tocagen's investor presentation, Dec 3, 2024
Slide 1: Forte Biosciences Corporate Deck
Exhibit 99.2 FORTE BIOSCIENCES FORTE BIOSCIENCES CORPORATE DECK DEC 3, 2024 1
Slide 2: Cautionary Note Regarding Forward-Looking Statements
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS ¡ Certain statements contained in this presentation regarding matters that are not historical facts, are forward-looking statements within the meaning of Section 21E of the Securities and Exchange Act of 1934, as amended, and the Private Securitie
Slide 3: Clinical Stage FB-102
CLINICAL STAGE FB-102 • CD122 is a subunit of the intermediate affinity IL-2/IL-15 receptor expressed on NK cells and T cells and is a subunit of the high affinity IL-2 receptor expressed on Tregs. • FB102 (Forte’s anti-CD122 antibody) is designed to mediate both the IL-2 and the IL-15 induced proli
Slide 4: Forte Biosciences Overview
FORTE BIOSCIENCES OVERVIEW • Strong Board of Directors comprised of leaders in industry including: • Scott Brun, MD – Former head of Abbvie product development • David Gryska – Former CFO of Incyte and Celgene • Barbera Finck, MD – Led Enbrel development at Immunex and Humira biosimilar development
Slide 5: Experienced Management
EXPERIENCED MANAGEMENT Forte’s management has extensive experience in manufacturing, quality, regulatory and clinical development Paul Wagner, Ph.D., CFA – CEO Tony Riley – Chief Financial Officer Chris Roenfeldt, PMP – Chief Operating Officer Steven Ruhl – Chief Technical Officer Barbara Finck, MD
Slide 6: FB102 CD122 Antagonist Mechanism
FB102 CD122 ANTAGONIST MECHANISM 6
Slide 7: Clinical Stage FB102 Overview
CLINICAL STAGE FB102 OVERVIEW • CD122 is a subunit of the intermediate affinity IL- 2/IL-15 receptor expressed on NK cells, certain T cell subtypes and is a subunit of the high affinity IL-2 receptor expressed on Tregs. • FB102 (Forte’s anti-CD122 antibody) is designed to mediate both the IL-2 and t
Slide 8: Advancing Clinical Stage FB102
ADVANCING CLINICAL STAGE FB102 • Phase 1 healthy volunteer SAD/MAD successfully completed and demonstrated a good safety profile. • Forte initiated a celiac disease patient study in 3Q24 and topline data is expected in 2Q25. • Significant amount of proof-of-concept preclinical data across numerous i
Slide 9: Highlights of Existing Preclinical Anti-CD122 Proof-of-Concept Data
HIGHLIGHTS OF EXISTING PRECLINICAL ANTI-CD122 PROOF- OF-CONCEPT DATA 9
Slide 10: Partial List of Positive POC Animal Data for Anti-CD122
PARTIAL LIST OF POSITIVE POC ANIMAL DATA FOR ANTI-CD122 HIGHLIGHTS FB102 “PIPELINE-IN-A-PRODUCT” POTENTIAL Disease Species Outcome Reference Celiac disease Mouse Improved IL-15-induced PNAS, 2009 mucosal damage Vitiligo Mouse Enhanced repigmentation Sci Transl Med, 2018 Alopecia areata Mouse Prevent
Slide 11: FB102 in Proof-of-Concept Autoimmune Preclinical Data
FB102 IN PROOF-OF-CONCEPT AUTOIMMUNE PRECLINICAL DATA 11
Slide 12: Preclinical Efficacy Data in Humanized Mouse Model of Acute GVHD
GENERATING PRECLINICAL EFFICACY DATA IN A HUMANIZED MOUSE MODEL OF ACUTE GVHD Humanized mouse model of graft vs host disease Aggressive, rapid-onset of GvHD (100% mortality within 30 days) due to both T and NK cell engraftment NCG (immunodeficient) Transplant with human 6 with human IL-15 expression
Slide 13: Dose-Ranging Investigation of FB102 in Humanized GVHD Mouse Model
DOSE-RANGING INVESTIGATION OF FB102 IN A HUMANIZED MOUSE MODEL OF ACUTE GVHD: THERAPEUTIC MODE Irradiation & End of PBMC transplantation treatment 1 2 3 4 5 6 8 10 12 13 14 Day 7 9 11 FB102 Once-daily IP administration Start dosing on Day 5, (75, 125, 175 mpk) once daily Vehicle Once-daily IP admini
Slide 14: FB102 Survival Benefits: Therapeutic Model
FB102 SURVIVAL BENEFITS: THERAPEUTIC MODEL FB102 Start of daily treatment superior to 1 1 1 1 10 0 0 0 00 0 0 0 0% % % % % FB102(75): 90% aGvHD FB102(175): 90% 8 8 8 8 80 0 0 0 0% % % % % FB102(125): 80% standard of care, 6 6 6 6 60 0 0 0 0% % % % % Ruxolitinib: 60% ruxolitinib, head to head 4 4 4 4
Slide 15: Mono vs Combination Therapies with FB102, Ruxolitinib or Corticosteroids
MONO VS COMBINATION THERAPIES WITH FB102, RUXOLITINIB OR CORTICOSTEROIDS Irradiation & End of study PBMC injection (D18) Day 1 5 8 12 15 18 Ruxolitinib Twice-daily oral (60 mpk) FB102+Ruxolitinib Once-daily IP + twice-daily oral (75 mpk+60 mpk) Placebo Once-daily IP + twice-daily oral (Combination o
Slide 16: FB102 Combination with Ruxolitinib Superior to Ruxolitinib Alone
FB102 SURVIVAL BENEFITS: COMBINATION OF FB102 WITH RUXOLITINIB SIGNIFICANTLY SUPERIOR TO RUXOLITINIB ALONE Start of daily treatment FB102/rux 100% 1 10 00 0% % combo FB102+Rux: 90% significantly 8 8 80 0 0% % % superior to standard of care 6 6 60 0 0% % % single agent, 4 4 40 0 0% % % ruxolitinib, R
Slide 17: In Vivo NHP and Human Healthy Volunteer Summary
IN VIVO NHP AND HUMAN HEALTHY VOLUNTEER SUMMARY 17
Slide 18: FB102 Phase 1 Healthy Volunteer Summary
FB102 PHASE 1 HEALTHY VOLUNTEER SUMMARY • Phase 1 healthy volunteer SAD/MAD successfully completed and demonstrated a good safety profile. • Significant reductions in NK cell pharmacodynamic marker of FB102 mechanism were observed supporting the in-vitro as well as the NHP data and the mechanism of
Slide 19: FB102 Indication Review
FB102 INDICATION REVIEW 19
Slide 20: Partial List of Positive POC Animal Data for Anti-CD122
PARTIAL LIST OF POSITIVE POC ANIMAL DATA FOR ANTI-CD122 HIGHLIGHTS FB102 “PIPELINE-IN-A-PRODUCT” POTENTIAL Disease Species Outcome Reference Celiac disease Mouse Improved IL-15-induced PNAS, 2009 mucosal damage Vitiligo Mouse Enhanced repigmentation Sci Transl Med, 2018 Alopecia areata Mouse Prevent
Slide 21: Celiac Disease
CELIAC DISEASE 21
Slide 22: No Approved Therapies for Celiac Disease; Significant Market Opportunity
NO APPROVED THERAPIES FOR CELIAC DISEASE; POTENTIAL FOR A SIGNIFICANT MARKET OPPORTUNITY ¡ Celiac disease ¡ Celiac disease is an autoimmune disease that’s triggered by consuming gluten and results in damage to the small intestine ¡ Symptom include diarrhea, fatigue, headaches, anemia, nausea, dermat
Slide 23: IL-2 and IL-15 in Celiac Disease
IL-2 AND IL-15 IN CELIAC DISEASE (CED) IL-2 ¡ Clear genetic basis for involvement of IL-2 in CeD ¡ Gluten-induced IL-2 production differentiates true CeD from non-gluten induced GI symptoms ¡ IL-2 strongly correlates with symptom severity and Serum IL-2 peaks within 4 hours after gluten exposure ¡ I
Slide 24: FB102: Prevention of Gluten-Induced Intestinal Damage by Blocking IL-15 and IL-2
FB102: PREVENTION OF GLUTEN-INDUCED INTESTINAL DAMAGE IN + CELIACS BY BLOCKING IL-15 AND IL-2 ACTIVATION OF CD8 T CELLS healthy epithelium damaged epithelium + CD8+ CD8 cells T cell IL-15 damage epithelium FB102 blocks IL-15 and IL-2 IL-2 Gluten APC with specific gluten + CD4 T cell peptide lamina p
Slide 25: Anti-CD122 Antibody Reverses IL-15 Induced Intestinal Damage in Mice
ANTI-CD122 ANTIBODY REVERSES IL-15 INDUCED INTESTINAL DAMAGE IN MICE ¡ Transgenic mice overexpressing IL-15 in the intestine have extensive inflammation and damage to the duodeno- jejunal region with extensive blunting of villi ¡ Extensive influx of NKG2D-expressing CD8+ T cells, and enterocytes exp
Slide 26: Trend for Reduced Villi Damage in Phase 1 MAD Gluten Challenge Celiac Patients
TREND FOR REDUCED VILLI DAMAGE IN PHASE 1 MAD GLUTEN CHALLENGE CELIAC PATIENTS TREATED WITH CALYPSO IL-15 ANTIBODY ¡ Patients who had received placebo show the expected decrease from baseline in VH:CD (mean CFB -0.69) in response to gluten challenge ¡ Patients who had received CALY-002 demonstrate a
Slide 27: FB102 Blocks Both IL-2 and IL-15, Advantages Over Other Drugs
FB102 BLOCKS BOTH IL-2 AND IL-15, PROVIDING ADVANTAGES OVER OTHER DRUGS BEING CLINICALLY INVESTIGATED FOR CELIAC DISEASE Immunomodulators Gluten Modification Immunotolerance Gut Healing Single targeting Multi targeting IMGX-003 TAK-101 IMU-856 IL-15 à CALY-002 CD122 (IL-2/IL-15)àFB102 TMP502 TAK-062
Slide 28: Celiac Disease FB102 Trial Overview
CELIAC DISEASE FB102 TRIAL OVERVIEW 28
Slide 29: Celiac Disease (Cohort C) Design
CELIAC DISEASE (COHORT C) DESIGN • Study currently enrolling 10 • ~10 sites • Topline data expected in 2Q25
Slide 30: Vitiligo
VITILIGO 30
Slide 31: Large Unmet Need in Vitiligo Presents Substantial Market Opportunity
LARGE UNMET NEED IN VITILIGO PRESENTS A SUBSTANTIAL MARKET OPPORTUNITY ¡ Vitiligo ¡ Vitiligo is an autoimmune disease of the skin driven by pathogenic T cells that kill melanocytes and create white spots. ¡ Vitiligo results in sensitive skin (increasing likelihood of sub burns), eye abnormalities, e
Slide 32: IL-15 Activation of Pathogenic CD8+ T Cells in Skin
IL-15 ACTIVATION OF PATHOGENIC CD8+ T CELLS IN SKIN Vitiligo patients have unpigmented skin due to activated FB102 blocks activation of pathogenic T cells, restoring pathogenic T cells killing melanocytes melanocyte health and skin pigmentation Tokura Front Immunol. 2021 PMID 33633737 32
Slide 33: IL-2 Therapy Drives Vitiligo
IL-2 THERAPY DRIVES VITILIGO Enhanced Survival Associated with Vitiligo Expression during (1) Maintenance Biotherapy for Metastatic Melanoma 1 2 1 1 2 1 Peter D. Boasberg , Dave S.B. Hoon , Lawrence D. Piro , Maureen A. Martin , Akhide Fujimoto , Timothy S. Kristedja , 1 2 1 1 Sandeep Bhachu , Xing
Slide 34: Anti-CD122 Antibody Effective in Mouse Vitiligo Model
AN ANTI-CD122 ANTIBODY IS EFFECTIVE IN A MOUSE VITILIGO MODEL WITH ESTABLISHED DISEASE Repigmentation study Melanin-reactive T cells Melanin-reactive T cells eliminated pigment in tail eliminated pigment in tail Vehicle (control) treatment Anti-CD122 treatment did not restore pigment restored pigmen
Slide 35: Anti-CD122 in Mouse Vitiligo Model: Durable Response with Infrequent Dosing
ANTI-CD122 IN A MOUSE MODEL OF VITILIGO: POTENTIAL OF DURABLE RESPONSE WITH INFREQUENT DOSING REGIMEN Note: anti-mouse CD122 (surrogate molecule) was used in these studies. 35
Slide 36: FB102 Unique MOA for Treating Vitiligo by Inhibiting Two Cytokines
FB102 HAS A UNIQUE MOA FOR TREATING VITILIGO BY INHIBITING TWO CYTOKINES TO REDUCE IMMUNE ATTACK OF MELANOCYTES Reducing Autoimmune Response JAK based Carries Black Box Warning Single Cytokine Multi Cytokine JAK 3/TEC à ritlecitinib (LITFULO) IL-17A à aixekizumab (Taltz), CD122 (IL-2/IL-15) à FB102
Slide 37: Alopecia Areata
ALOPECIA AREATA 37
Slide 38: Large Unmet Need in Alopecia Areata Presents Significant Market Opportunity
LARGE UNMET NEED IN ALOPECIA AREATA PRESENTS A SIGINIFICANT MARKET OPPORTUNITY ¡ Alopecia Areata ¡ Alopecia areata is a common autoimmune disease that occurs when pathogenic T cells attack hair follicles causing hair loss. ¡ Alopecia areata affects both men and women and affects all racial and ethni
Slide 39: Alopecia Areata Is Driven by T Lymphocytes Invading Hair Follicles
ALOPECIA AREATA (AA) IS DRIVEN BY T LYMPHOCYTES INVADING HAIR FOLLICLES ¡ A healthy hair bulb in anagen phase of the Left: Co-expression of hair follicle cycle is surrounded by an IL-15 and IL-15RA in alopecia areata (AA) but immunosuppressive environment (an not normal control immune privileged spa
Slide 40: FB102 Should Protect Hair Follicles from Immune Attack
FB102 SHOULD PROTECT HAIR FOLLICLES FROM IMMUNE ATTACK AFTER LOSS OF IMMUNE PRIVILEGE 40
Slide 41: Anti-CD122 or Anti-IL-2 Antibodies Prevent Hair Loss in Mouse Model
ANTI-CD122 OR ANTI-IL-2 ANTIBODIES PREVENT HAIR LOSS IN A MOUSE MODEL OF VITILIGO ¡ C3H/HeJ mice spontaneously express alopecia with age with about 20% penetrance ¡ Grafting C3H/HeJ skin from a mouse with alopecia to mice that have not developed alopecia results in rapid disease onset (21 to 35 days
Slide 42: Competitive Pipeline
COMPETITIVE PIPELINE Reducing Autoimmune Response JAK based Carries Black Box Warning Single Target Multi Target JAK 3/TEC à ritlecitinib (LITFULO) S1P à etrasimod (VELSIPITY) CD122 (IL-2/IL-15) à FB102 JAK 1/2 à baricitinib (Olumiant) OX40 à IMG-007 IL-4/13 à dupilumab (Dupixent) JAK 1/2 à deuruxol
Slide 43: Type 1 Diabetes
TYPE 1 DIABETES 43
Slide 44: Type 1 Diabetes Caused by Autoreactive T Cells Destroying Beta Cells
TYPE 1 DIABETES IS CAUSED BY AUTOREACTIVE T CELLS DESTROYING INSULIN-PRODUCING PANCREATIC BETA CELLS ¡ Type 1 diabetes (T1D) is classified by three stages of progression ¡ Stage 1: at least one diabetes-related autoantibody but has normal blood sugar and no symptoms ¡ Stage 2: at least two diabetes-
Slide 45: Type 1 Diabetes Clinical Competitive Space
TYPE 1 DIABETES CLINICAL COMPETITIVE SPACE From TZIELD PI • The 2 approved products both carry significant challenges in their safety profile. • LANTIDRA • cell therapy that requires hospitalization for administration and cost $300K/cycle • 90% of subjects experience serious AEs • TZIELD • IV infusi
Slide 46: FB102 Inhibits IL-15/IL-2 from Activating Beta-Cell Specific CD8+ T Cells
BASED ON THE MOA, FB102 INHIBITS IL-15/IL-2 CYTOKINE FROM ACTIVATING BETA-CELL SPECIFIC CD8+ T CELLS, PREVENTING BETA-CELL KILLING IL-15/ FB102 blocks IL15RA IL-15 binding CD122/ CD132 CD8+ T cells with receptors recognizing Environmental stress causes β-cells to β-cell specific peptides are enriche
Slide 47: Single Injection of Anti-CD122 Delays Diabetes Onset in NOD Mice
A SINGLE INJECTION OF ANTI-CD122 ANTIBODY DELAYS DIABETES ONSET IN NOD MICE AND ALSO KNOCKS DOWN NK CELLS Yuan 2018 JCI Insight PMID 29367461 47
Slide 48: Summary
SUMMARY 48
Slide 49: Clinical Stage FB-102
CLINICAL STAGE FB-102 • CD122 is a subunit of the intermediate affinity IL-2/IL-15 receptor expressed on NK cells and T cells and is a subunit of the high affinity IL-2 receptor expressed on Tregs. • FB102 (Forte’s anti-CD122 antibody) is designed to mediate both the IL-2 and the IL-15 induced proli
Forte Biosciences — Investor Presentation (December 2024) on 6ix